Compare United States Copper Index Fund (CPER) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Summit Therapeutics Inc — how do they compare? United States Copper Index Fund trades at $40.08, while Summit Therapeutics Inc trades at $15.22 (market cap $12.06B). The key difference: United States Copper Index Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| CPER | SMMT | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $40.85 | $26.98 |
52-Week Low | $27.57 | $12.55 |
Market Cap | — | $12.06B |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER (United States Copper Index Fund) trades at $40.345, up 0.41% with a bullish technical signal supported by moving averages. The copper market faces supply constraints from Chilean weather disruptions while AI and electrification demand drives prices to record highs. Recent news highlights copper's structural bull case with Citi targeting $15,000/tonne by year-end.
Copper's fundamental outlook remains strong due to AI infrastructure demand and supply constraints, though substitution risks and geopolitical tensions present headwinds. The ETF offers pure copper exposure amid favorable analyst sentiment, with technical indicators suggesting continued upward momentum near key resistance levels.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
